• Explore /
  • Poster
  • / A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

A phase 1b study of the OxPhos inhibitor ME-344 in combination with bevacizumab in refractory metastatic colorectal cancer.

Abstract Poster

Authors

null

Patrick M Boland

Rutgers Cancer Institute of New Jersey, New Brunswick, NJ

Patrick M Boland , Heinz-Josef Lenz , Mike Cusnir , Vaia Florou , Michael J. Pishvaian , Deirdre J. Cohen , Kristen Keon Ciombor , Arthur Winer , Jessie Yanxiang Guo , Sandra Algaze , Sandra E Wiley , Richard Ghalie , Howard S. Hochster

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2024 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Colorectal Cancer,Anal Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT02100007

Citation

J Clin Oncol 42, 2024 (suppl 3; abstr TPS222)

DOI

10.1200/JCO.2024.42.3_suppl.TPS222

Abstract #

TPS222

Poster Bd #

N10

Abstract Disclosures

Similar Posters

First Author: Hirokazu Shoji

First Author: Kayo Yasuda

First Author: Yasutoshi Kuboki

First Author: Nieves Martinez Lago